If you are not happy with the results below please do another search
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is based in the UK with offices at the Sussex Innovation Centre.
- Enterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical OfficerFebruary 8, 2022 - 8:00 am
- Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001June 14, 2021 - 9:00 am
- Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by RocheOctober 7, 2020 - 7:02 am
- Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002August 17, 2020 - 9:00 am
Follow Us On Twitter
Why have previous attempts to target ENaC in the lungs of #CysticFibrosis patients failed?
Don't miss @EnterpriseThera's Henry Danahay describe ETD001, a long acting inhaled ENaC blocker with the opportunity to treat all #CF patients, at @ECFSConference: https://rb.gy/soo8mk